Thematic Insights: China Immunotherapy Competition

THIS MATERIAL IS A MARKETING COMMUNICATION.

Thematic Insights: China Immunotherapy Competition

In this video, we will discuss the competitive immunotherapy landscape in China.

Market Potential

China’s PD(-L)1(programmed cell death protein 1) sales are expected to grow at 36% compound annual growth rate (CAGR) 2020-25e to RMB 62 billlon (vs. 2020e is expected to be RMB13 billion). This rapid growth will be mainly be driven by (i) significant medical demand to address a large patient population; (ii) favorable regulatory reforms to drive faster launches, with bigger/wider indication coverages; and (iii) reimbursement expansion, bridging the gap between demand and supply. Lung cancer, stomach cancer, Oesophagus cancer, and liver cancer, in total, represent about 55% of new cancer cases in China.

In China, there are 142 PD-(L)1/ PDL1(programmed death-ligand 1) inhibitor-related later-stage clinical trials ongoing, targeting cancer sites with higher incidence and frontline/(neo) adjuvant treatment, compared to only a handful that has been approved so far, that too for only a small number of indications. These clinical trials are aiming for wider patient coverage. We are positive on PD-(L)1’s efficacy in the frontline treatment of major cancer types as well as in adjuvant settings. We think the leading domestic players are well placed relative to the competition.

Considering the various combo therapies in different cancer indications, we believe that the PD-(L)1 inhibitor as an immune modulator would likely play a basic role in carrying various other innovative drugs for oncology treatment.

Companies that can consistently develop newer treatment modalities, provide low-cost, high-quality drugs, and have strong academic-based sales teams should be able to capture market share.

Four leading domestic companies are leading the way in approvals as well as in key large indications.

As we can see from this table, while multinational companies were initially leading, four domestic companies have got approval for their PD1 molecule.

We detail below two large key indications (lung and stomach) and discuss progress among Chinese companies.

Lung cancer has the highest incidence worldwide and is well-studied by MNCs (multinational companies). It is getting competitive in China, but MNCs have taken the lead so far.

Hengrui, Innovent, and BeiGene are the Tier 1 domestic players, with indications approved or filed already. We believe, once these domestic companies get approved and included in reimbursement, they will be able to penetrate into tier 2/3 cities before the second wave of approvals come in, thereby creating a strong entry barrier.

In this table, we can see that domestic companies are catching up to multinational companies.

Stomach cancer is the second most prevalent cancer type in China, and new cases comprise 50% of the total incidence worldwide. (UBS Research, 13 Jan 2021).

Research & Devleopment (R&D) capability is the key driver for the development and successful launch of innovative medicines. By 1H2020, BeiGene had the largest R&D team (400+ in research and 1,350+ in clinical development), while the R&D teams at Innovent and Junshi are also growing.(1H2020 is the date) In terms of R&D expenditure, BeiGene, Innovent, and Junshi spent Rmb6.4billion, Rmb1.3billion, and Rmb0.9billion, respectively, in 2019.

As we can see in these charts, the three domestic companies have progressed well in strengthening their R&D efforts as well as developing the commercial sales team.

In summary, we continue to be impressed with the pace at which domestic Chinese companies have progressed on developing an immunotherapy pipeline, including PD1 molecules as well as combination therapies.

Thematic Insights: China Immunotherapy Competition

In this video, we will discuss the competitive immunotherapy landscape in China.

Market Potential

China’s PD(-L)1(programmed cell death protein 1) sales are expected to grow at 36% compound annual growth rate (CAGR) 2020-25e to RMB 62 billlon (vs. 2020e is expected to be RMB13 billion). This rapid growth will be mainly be driven by (i) significant medical demand to address a large patient population; (ii) favorable regulatory reforms to drive faster launches, with bigger/wider indication coverages; and (iii) reimbursement expansion, bridging the gap between demand and supply. Lung cancer, stomach cancer, Oesophagus cancer, and liver cancer, in total, represent about 55% of new cancer cases in China.

In China, there are 142 PD-(L)1/ PDL1(programmed death-ligand 1) inhibitor-related later-stage clinical trials ongoing, targeting cancer sites with higher incidence and frontline/(neo) adjuvant treatment, compared to only a handful that has been approved so far, that too for only a small number of indications. These clinical trials are aiming for wider patient coverage. We are positive on PD-(L)1’s efficacy in the frontline treatment of major cancer types as well as in adjuvant settings. We think the leading domestic players are well placed relative to the competition.

Considering the various combo therapies in different cancer indications, we believe that the PD-(L)1 inhibitor as an immune modulator would likely play a basic role in carrying various other innovative drugs for oncology treatment.

Companies that can consistently develop newer treatment modalities, provide low-cost, high-quality drugs, and have strong academic-based sales teams should be able to capture market share.

Four leading domestic companies are leading the way in approvals as well as in key large indications.

As we can see from this table, while multinational companies were initially leading, four domestic companies have got approval for their PD1 molecule.

We detail below two large key indications (lung and stomach) and discuss progress among Chinese companies.

Lung cancer has the highest incidence worldwide and is well-studied by MNCs (multinational companies). It is getting competitive in China, but MNCs have taken the lead so far.

Hengrui, Innovent, and BeiGene are the Tier 1 domestic players, with indications approved or filed already. We believe, once these domestic companies get approved and included in reimbursement, they will be able to penetrate into tier 2/3 cities before the second wave of approvals come in, thereby creating a strong entry barrier.

In this table, we can see that domestic companies are catching up to multinational companies.

Stomach cancer is the second most prevalent cancer type in China, and new cases comprise 50% of the total incidence worldwide. (UBS Research, 13 Jan 2021).

Research & Devleopment (R&D) capability is the key driver for the development and successful launch of innovative medicines. By 1H2020, BeiGene had the largest R&D team (400+ in research and 1,350+ in clinical development), while the R&D teams at Innovent and Junshi are also growing.(1H2020 is the date) In terms of R&D expenditure, BeiGene, Innovent, and Junshi spent Rmb6.4billion, Rmb1.3billion, and Rmb0.9billion, respectively, in 2019.

As we can see in these charts, the three domestic companies have progressed well in strengthening their R&D efforts as well as developing the commercial sales team.

In summary, we continue to be impressed with the pace at which domestic Chinese companies have progressed on developing an immunotherapy pipeline, including PD1 molecules as well as combination therapies.

AUTHORED BY
Saniel Chandrawat
Senior Investment Analyst – Healthcare, Energy, Utilities

Date: May 10, 2021
Category: Biotechnology, Video

Disclaimer

This document has been prepared for presentation; illustration and discussion purpose only and is not legally binding. Whilst complied from sources Mirae Asset Global Investments believes to be accurate, no representation, warranty, assurance or implication to the accuracy, completeness or adequacy from defect of any kind is made. Unless indicated to the contrary, all figures are unaudited. The division, group, subsidiary or affiliate of Mirae Asset Global Investments which produced this document shall not be liable to the recipient or controlling shareholders of the recipient resulting from its use. The views and information discussed or referred in this report are as of the date of publication, are subject to change and may not reflect the current views of the writer(s). the views expressed represent an assessment of market conditions at a specific point in time, are to be treated as opinions only and should not be relied upon as investment advice regarding a particular investment or markets in general. In addition, the opinions expressed are those of the writer(s) and may differ from those of other Mirae Asset Global Investments’ investment professionals.

The provision of this document shall not be deemed as constituting any offer, acceptance, or promise of any further contract or amendment to any contract which may exist between the parties. The issuer of this article is Mirae Asset Global Investments (HK) Limited (“we”) which the individual, or we or our managed funds may hold the mentioned securities. It should not be distributed to any other party except with the written consent of Mirae Asset Global Investments. Nothing herein contained shall be construed as granting the recipient whether directly or indirectly or by implication, any license or right, under any copy right or intellectual property rights to use the information herein. This document may include reference data from third-party sources and Mirae Asset Global Investments has not conducted any audit, validation, or verification of such data. Mirae Asset Global Investments accepts no liability for any loss or damage of any kind resulting out of the unauthorized use of this document. Investment involves risk. Past performance figures are not indicative of future performance. Forward-looking statements are not guarantees of performance. The information presented is not intended to provide specific investment advice. Please carefully read through the offering documents and seek independent professional advice before you make any investment decision. Products, services, and information may not be available in your jurisdiction and may be offered by affiliates, subsidiaries, and/or distributors of Mirae Asset Global Investments as stipulated by local laws and regulations. Please consult with your professional adviser for further information on the availability of products and services within your jurisdiction.

Australia: The information contained on this document is provided by Mirae Asset Global Investments (HK) Limited (“MAGIHK”), which is exempt from the requirement to hold an Australian financial services license under the Corporations Act 2001 (Cth) (Corporations Act) pursuant to ASIC Class Order 03/1103 (Class Order) in respect of the financial services it provides to wholesale clients (as defined in the Corporations Act) in Australia. MAGIHK is regulated by the Securities and Futures Commission of Hong Kong under Hong Kong laws, which differ from Australian laws. Pursuant to the Class Order, this document and any information regarding MAGIHK and its products is strictly provided to and intended for Australian wholesale clients only. The content of this document is prepared by Mirae Asset Global Investments (HK) Limited and has not been reviewed by the Australian Investments & Securities Commission.

Hong Kong: Before making any investment decision to invest in the Fund, investors should read the Fund’s Prospectus and the Information for Hong Kong Investors of the Fund for details and the risk factors. Investors should ensure they fully understand the risks associated with the Fund and should also consider their own investment objective and risk tolerance level. Investors are also advised to seek independent professional advice before making any investment. This document is issued by Mirae Asset Global Investments and has not been reviewed by the Hong Kong Securities and Futures Commission.

Singapore: It is not intended for general public distribution. The investment is designed for Accredited Investors as defined under the Securities and Futures Act of Singapore. Please consult with your professional adviser for further information on the availability of products and services within your jurisdiction.